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ABSTRACT 
 
Background 
The role of vitamin D in cancer risk remains controversial. Importantly, there are limited data on the 
associations between vitamin D and subtypes of specific cancers.  
 
We investigated associations between circulating vitamin D and risk of colorectal, breast, and prostate 
cancers, including cancer subtypes, in an Australian cohort. 
 
Methods 
We conducted a case-cohort study within the Melbourne Collaborative Cohort Study, including 547 
colorectal cancer cases, 634 breast cancer cases, and 824 prostate cancer cases, and a sex-stratified 
random sample of cohort participants (n=2,996). Concentration of 25(OH)D in dried blood spots from 
baseline blood samples was measured using liquid chromatography-tandem mass spectrometry. Cox 
regression yielded adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for colorectal, 
breast, and prostate cancers in relation to plasma-equivalent 25(OH)D concentration. Competing risks 
models were used to examine associations by stage and BRAF/KRAS status for colorectal cancer, 
estrogen receptor status for breast cancer, and aggressiveness for prostate cancer. 
 
Results 
25(OH)D concentrations were inversely associated with risk of colorectal cancer (highest versus lowest 
25(OH)D quintile: HR = 0.71, 95% CI 0.51-0.98), which was limited to women (HR=0.52, 95% CI 
0.33-0.82). Circulating 25(OH)D was also inversely associated with BRAF V600E positive colorectal 
cancer (per 25 nmol/L increment: HR 0.71, 95% CI 0.50-1.01). There were no inverse associations with 
breast cancer (HR=0.98, 95% CI 0.70-1.36) or prostate cancer (HR=1.11, 95% CI 0.82-1.48). 
 
Conclusions 
Circulating 25(OH)D concentration appears to be inversely associated with colorectal cancer risk for 
women, but not with risk of breast cancer or prostate cancer. 
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Introduction 
Many observational studies have investigated associations between vitamin D status and risk of cancer, 
but results have been inconsistent (1,2). Vitamin D status is generally assessed by serum or plasma 25-
hydroxyvitamin D (25(OH)D) concentration because this metabolite is the main circulating form of 
vitamin D (with a half-life of 2-3 weeks) and reflects vitamin D from both cutaneous synthesis during 
UV exposure and exogenous sources (food and supplements) (3). The most commonly investigated 
cancers have been colorectal cancer, breast cancer, and prostate cancer (4). While there is suggestion 
of an inverse association of 25(OH)D with colorectal cancer, associations for breast cancer and prostate 
cancer are unclear (1,4,5). In addition, it is possible that associations might differ according to cancer 
subtypes, yet few studies have assessed associations by tumour characteristics such as stage (or disease 
aggressiveness in prostate cancer), somatic gene mutations (such as BRAF or KRAS) in colorectal 
cancer, and hormone receptor status in breast cancer (5).  
 
Using a cohort of middle-aged Australians, we prospectively investigated the association between 
circulating 25(OH)D concentration and risk of incident breast, prostate, and colorectal cancers and 
examined associations by cancer subtypes. 
 
Methods 
Participants 
The Melbourne Collaborative Cohort Study (MCCS) is a prospective cohort study of 41,513 residents 
of Melbourne, Australia, aged 27-76 (mean 55) years at recruitment (1990-1994). Details of the MCCS 
have been published (6). At baseline, participants attended clinics where they completed questionnaires 
on lifestyle and medical history as well as a 121-item food frequency questionnaire. Anthropometric 
measurements were performed by trained staff according to a standard protocol. Blood samples were 
collected from 41,113 (99%) participants; from the second year of study recruitment (from 1991 
onwards, for about 75% of participants), whole blood was spotted onto Guthrie cards, which were air 
dried and stored at room temperature in dark conditions. The Cancer Council Victoria’s Human 
Research Ethics Committee approved the study protocol and participants provided written informed 
consent.  
 
Information about screening tests was not obtained at baseline. In a second wave of data collection 
about four years after baseline, participants completed a questionnaire that asked about mammography, 
prostate-specific antigen (PSA) tests, sigmoidoscopy, colonoscopy and faecal occult blood tests 
(FOBT). 
 
A case-cohort design was adopted for the vitamin D study (7). Participants with no pre-baseline 
diagnosis of cancer and for whom a baseline dried blood spot (Guthrie card) sample was available were 
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eligible (n = 29,205). The subcohort comprised random samples of 1332 women (7.84% of 16,976) and 
1664 men (13.6% of 12,229), chosen to be proportionate to the expected number of cases of breast and 
prostate cancer, respectively. Vital status was determined from linkage to the Registry of Births, Deaths 
and Marriages Victoria and the National Death Index. Participants for whom vitamin D measurements 
were not performed and those with missing data for potential confounders were excluded from analyses.  
 
Ascertainment and classification of cancers 
Cases comprised all eligible participants who had a primary, histologically confirmed invasive 
adenocarcinoma of the colon or rectum, breast, or prostate diagnosed by 31 December 2007 and notified 
to the Victorian Cancer Registry. The Registry classifies all three tumour types according to stage and 
records grade (plus Gleason score in the case of prostate cancer) for all histopathologically confirmed 
tumours.  We attempted to obtain archival tumour tissue for all cancers. 
 
For colorectal cancer, the V600E BRAF mutation, which accounts for approximately 90% of BRAF 
mutations in colorectal cancer (8), was measured in DNA extracted from archival tumour tissue using 
a real-time PCR-based allelic discrimination method (9,10). Somatic mutations in codons 12 and 13 of 
KRAS were identified using real-time PCR with high-resolution melting analysis followed by direct 
Sanger sequencing on cases with differential melting profiles (11).  
 
The Registry routinely records information on estrogen receptor (ER) and progesterone receptor (PR) 
status of breast tumours, although in the early years of follow-up, reporting was incomplete. For cases 
with archival tissue available (67% of all cases), we repeated the measurement of ER and PR status 
using immunohistochemistry (12). Because the agreement between the ER status assessed from the 
archival tumour tissue and the values on the original pathology reports held by the Victorian Cancer 
Registry was high (89%, kappa = 0.71 ) (12), ER and PR status recorded by the Registry was used when 
archival tumour tissue was not available. 
 
Assessment of 25-hydroxyvitamin D 
Concentration of 25(OH)D from baseline dried blood spot samples was measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) in the laboratory of D.W.E. as previously 
described (13,14). Measurements were performed over 15 months in 31 batches of approximately 230 
samples each. The laboratory routinely calibrates relative accuracy using National Institute of Standards 
and Technology standard reference materials and participates in the Vitamin D External Quality 
Assessment Scheme. Samples were processed in random order and laboratory analysts were blind to 
outcome status of participants. Reliability was assessed using repeat measurements on 493 subcohort 
members for whom duplicate samples were randomly interspersed throughout the samples. As 
previously reported, the within- and between-batch intraclass correlations were 0.82 (95 % CI 0.80-
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0.85) and 0.73 (95% CI 0.68-0.78), respectively (14). Methods used for removing batch and seasonal 
effects in 25(OH)D measurements and conversion to plasma equivalent concentrations have been 
described (7,14). All results presented are for batch- and season-adjusted plasma-equivalent 25(OH)D. 
 
Statistical analysis 
Follow up began at baseline and ended at diagnosis of the cancer under study, date of leaving Australia, 
death, or 31 December 2007, whichever came first. Hazard ratios (HRs) and 95% confidence intervals 
(CIs) were estimated using Cox regression. Barlow weights, with robust standard errors, were used to 
account for the case-cohort design (15). Batch- and season-adjusted plasma 25(OH)D was categorised 
into five groups, based on the sex-specific quintiles of the subcohort. We also modelled the association 
between continuously-valued 25(OH)D and cancer risk. Cases for each cancer type were compared with 
the full subcohort (for colorectal cancer analyses), or female portion of the subcohort (breast cancer), 
or male portion of the subcohort (prostate cancer). To control for confounding by age, attained age was 
used as the timescale in all Cox regression models (16). All models were stratified by country of birth 
(Australia/New Zealand/UK or southern Europe) and sex (for colorectal cancer), and further adjusted 
for the following potential confounding factors measured at recruitment: educational attainment 
(primary school, some high/technical school, completed high school, and completed tertiary 
degree/diploma), socioeconomic status (quintiles of relative disadvantage based on area of residence), 
physical activity (four ordered categories reflecting frequency and intensity of physical activity), 
smoking status (never, former, current), alcohol consumption (lifetime abstainer, former drinker, 
current low, current medium, current high, with the latter three determined by sex-specific tertiles in 
the subcohort), and waist circumference (grouped by sex-specific quartiles in the subcohort). Colorectal 
cancer analyses further adjusted for margarine intake (grouped by quartiles in the subcohort) and intake 
of processed meat (grouped by quartiles in the subcohort), and excluded participants deemed to have 
outlying total energy intakes reported in the Food Frequency Questionnaire (˂1st and >99th sex-specific 
percentiles). Breast cancer analyses further adjusted for parity (any children versus none), use of oral 
contraceptives (never, former, current), hormone replacement therapy (never, former, current), age at 
baseline clinic attendance (˂55 versus ≥55 years) and an interaction between this variable and waist 
circumference.  
 
For colorectal cancer, we tested an interaction of 25(OH)D with sex. The proportional hazards 
assumption was assessed by fitting interactions between each covariate separately (modelled as a time 
varying effect) and attained age. There was no evidence that any covariate violated the assumptions. 
 
Further analyses investigated whether HRs differed by cancer subtype, using competing risks models 
based on a data duplication approach (17). Differences in HRs by cancer subtypes were evaluated using 
Wald tests. For colorectal cancer, we compared associations between BRAF+, KRAS+ and BRAF- 
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/KRAS- cancers (only 3 tumours were KRAS+/BRAF+), and between stage I/II and stage III/IV cancers. 
For breast cancer, we compared ER+ and ER- tumours. We did not analyse PR status because it was 
strongly associated with ER status and only 19 cases were PR+ but ER-. We did not analyse stage for 
breast cancer because almost all cases were stage I or II, which both have similar, very high survival. 
For prostate cancer, we compared aggressive (defined as died from prostate cancer by 31 December 
2016; Gleason score > 7 or poorly differentiated or undifferentiated tumour; TNM stage: T4, N+ or 
M+) and non-aggressive cancer. Due to limited numbers of some tumour subtypes, results of these 
analyses are only presented for 25(OH)D modelled continuously (results were similar for categorical 
25(OH)D). 
 
Sensitivity analyses investigated: (i) change in the HRs by time since baseline attendance (0-4, 5-9, and 
10+ years) and (ii) HRs after excluding the first year of follow-up.  To determine whether screening 
tests might have confounded the associations, we undertook an analysis of screening behaviours 
reported at wave 2, restricted to subcohort participants who had not been diagnosed with the relevant 
cancer (i.e., colorectal, breast or prostate) before completing the questionnaire. 
 
All analyses were performed using Stata 14.2 (StataCorp, College Station, USA). 
 
Results 
During follow-up (median 14 years in the subcohort), of 29,205 eligible participants, 562 had incident 
diagnoses of colorectal cancer (74 of which occurred in the random subcohort), 659 women were 
diagnosed with breast cancer (62 in the subcohort), and 833 men with prostate cancer (123 in the 
subcohort). After exclusions, 547 colorectal, 634 breast, and 824 prostate cancer cases were included 
in analyses (Figure 1). Baseline characteristics of subcohort participants and those diagnosed with these 
cancers are shown in Table 1. Subcohort participants and those who developed cancer did not differ 
substantially with respect to important confounders, with the following exceptions: colorectal cancer 
cases were older, and of these, female cases were more likely to be current smokers, while male cases 
were less likely to be current smokers but more likely to have high alcohol intake; prostate cancer cases 
were less likely to be current smokers; and breast cancer cases were more likely to be born in 
Australia/New Zealand/Northern Europe. 
 
Circulating 25(OH)D concentrations were not associated with risk of breast cancer or prostate cancer 
(Table 2). There was an inverse association with incident colorectal cancer (HR for highest compared 
with lowest 25(OH)D quintile = 0.71, 95% CI 0.51-0.98), which was evident for women (HR = 0.52, 
95% CI 0.33-0.82), but not men (HR = 0.96, 95% CI 0.61-1.52), although the p-value from the 
25(OH)D×sex interaction was large (p = 0.45).  
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Stage was available for 509 (91%) colorectal cancer cases, while BRAF and KRAS status were 
available for 425 (77%) cases. In competing risks analyses, the inverse association between 25(OH)D 
concentration and colorectal cancer did not significantly differ by stage (Figure 3). While there was no 
inverse association with BRAF-/KRAS- colorectal cancer (HR per 25 nmol/L increase in 25(OH)D = 
0.98, 95% CI 0.77-1.24), or KRAS+ colorectal cancer (HR = 1.17, 95% CI 0.91-1.52), circulating 
25(OH)D concentration was inversely associated with BRAF+ colorectal cancer (HR = 0.71, 95% CI 
0.50-1.01; p = 0.05) (p heterogeneity = 0.07). Information on ER was available for 586 (92%) breast 
cancers. There was little evidence that 25(OH)D concentration was associated with ER negative or ER 
positive breast cancer (Figure 3). Almost all prostate cancers (n=817, 99%) could be classified as 
aggressive or non-aggressive. There was a weak statistically non-significant positive association with 
non-aggressive disease, but no association with aggressive disease (Figure 3).  
 
Results did not differ significantly by time since baseline blood collection for any of the cancers (Figure 
2). After excluding the first year of follow-up after baseline, the HRs for 25(OH)D modelled 
continuously were almost identical to their respective values from the main analysis. The largest change 
was in the HR for colorectal cancer for women, which was 0.73 (CI 0.54-1.00) per 25 nmol/L compared 
with 0.75 (0.56-1.02) for the whole sample. 
 
The second wave questionnaire was completed by 2639 (88%) of the 2996 subcohort participants 
including 1147 (87%) men and 1192 (89%) women. About 20% reported FOBT, sigmoidoscopy or 
colonoscopy (21% of men and 22% of women), 80% of women reported a mammogram and 34% of 
men reported a PSA test. Mean 25(OH)D concentrations were similar for participants who had 
screening tests and for those who did not: for colorectal cancer tests, the means were 51.4 nmol/L and 
52.0 nmol/L (p = 0.52) respectively; the means were 45.6 and 44.1 (p = 0.14) for women who had a 
mammogram and who did not; the means were 58.5 and 58.2 for men reporting and not reporting a PSA 
test (p = 0.27). 
 
Discussion 
In this cohort of middle-aged Australians, pre-diagnostic circulating 25(OH)D concentration was not 
associated with risk of breast cancer or prostate cancer but was inversely associated with risk of 
colorectal cancer for women but not men.   
 
Evidence on the association between circulating 25(OH)D concentration and cancer has mainly come 
from European and North American studies, many of which lacked precision and sufficient follow-up 
time, or have not examined associations by cancer subtypes. Strengths of our study include its 
prospective design, long follow-up, accurate quantification of 25(OH)D using LC-MS/MS, and 
extensive data on potential confounders. Detailed histopathology data, including tumour stage and the 
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presence or absence of the BRAF V600E and KRAS codon 12 and 13 somatic mutations for colorectal 
cancer, ER status for breast cancer, and aggressiveness for prostate cancer, enabled investigation of 
associations by cancer subtypes. A limitation was the use of a single 25(OH)D measurement, which 
may lose predictive power over time (18). However, studies have reported intra-individual consistency 
between 25(OH)D concentrations measured several years apart (19-22). Therefore, although repeated 
measurements would be ideal, a single measurement of 25(OH)D at baseline can provide a reasonable 
representation of an individual’s typical 25(OH)D concentration throughout a long-term 
epidemiological study. Reported absolute 25(OH)D concentrations should be interpreted with caution 
as these were plasma-equivalent concentrations estimated from measurements of 25(OH)D in dried 
blood spots and adjusted for batch and seasonal effects. The null findings for breast cancer and prostate 
cancer are unlikely to be due to an artefact of the 25(OH)D assay method or to the single time point 
since our measurements have yielded results consistent with existing literature for all-cause mortality 
and type 2 diabetes (7,23). In addition, as discussed below, the findings for incident colorectal cancer 
are similar to those from other prospective studies (24), further supporting the robustness of the 
25(OH)D measurements. Although we controlled for important potential confounders, we cannot 
exclude the possibility of residual confounding. The results of our analysis of 25(OH)D in relation to 
screening tests suggests that screening behaviour is not likely to confound any of the associations. 
 
Our results are consistent with those from other prospective studies, demonstrating a lower risk of 
incident colorectal cancer associated with higher 25(OH)D (25), but no evidence of a reduced risk for 
incident breast cancer or prostate cancer (4,5). An umbrella review of vitamin D and multiple health 
outcomes concluded that there was suggestive evidence that higher vitamin D concentrations might be 
associated with a lower risk of colorectal cancer; stronger evidence could not be inferred due to the 
absence of meta-analyses of randomised controlled trials of vitamin D supplementation and cancer 
outcomes (1). The same review concluded that it is unlikely that vitamin D has a substantial effect on 
prostate cancer or that it decreases the risk of aggressive prostate cancer. There was inadequate evidence 
to draw conclusions for breast cancer (1).  
 
We found no evidence that circulating 25(OH)D was associated with risk of incident breast cancer, 
which is consistent with null results from other prospective studies (4). The VITAL trial also found no 
effect of vitamin D supplementation on risk of breast cancer (relative risk = 1.02, CI 0.79-1.1.31), but 
its results were imprecise due to only 246 cases (26). Concentration of 25(OH)D was not associated 
with risk of prostate cancer overall or aggressive prostate cancer.  There is some evidence that the 
association might vary with calcium intake (27,28), but results have been inconsistent. We were unable 
to assess possible effect modification by calcium intake due to a lack of data on calcium 
supplementation. A Mendelian randomisation study found little evidence that genetically-determined 
25(OH)D concentration is associated with total or aggressive prostate cancer risk (29). The VITAL trial 
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reported a relative risk of 0.88 (CI 0.72-1.07) for prostate cancer based on 411 cases (26). Taken 
together, the lack of clear evidence for an association with prostate cancer overall or with aggressive 
disease suggests that it is unlikely that vitamin D is causally associated with incident prostate cancer. 
 
Although we did not find strong evidence of a linear association between 25(OH)D and colorectal 
cancer risk, there was a 29% decreased risk comparing the highest with lowest 25(OH)D quintile (HR 
= 0.71, 95% CI 0.51-0.98). This closely agrees with the association reported by a pooling project of 
participant-level data from 17 prospective cohort studies, including 5706 colorectal cancer case 
participants and 7107 control participants (pooled relative risk (RR) comparing highest with lowest 
25(OH)D quintile = 0.71, 95% CI 0.62-0.81) (24). It is also consistent with a meta-analysis of 15 cohort 
and nested case-control studies, which reported a 33% lower risk of colorectal cancer comparing the 
highest with lowest 25(OH)D quantile (pooled odds ratio = 0.67, 95% CI 0.59-0.76) (25). The point 
estimate in a Mendelian randomisation study was similar to that found in our study (OR per 25 nmol/L 
increase in genetically-determined 25(OH)D = 0.92); although the study was imprecise, the CI was 
consistent with a moderate inverse association (95% CI 0.76-1.10) (29). On the other hand, the VITAL 
trial found no effect of vitamin D supplementation on risk of colorectal cancer (relative risk = 1.09, CI 
0.73-1.62), but identified only 98 cases (26). 
 
Until recently, there has been limited evidence for a sex-specific association of vitamin D with 
colorectal cancer risk (4). The pooling project comprising 17 prospective cohort studies reported an 
inverse association between 25(OH)D concentration and colorectal cancer that was significantly 
stronger for women (pooled relative risk (RR) per 25 nmol/L increment in 25(OH)D = 0.81, 95% CI 
0.75-0.87), than for men (RR = 0.93, 95% CI 0.86-1.00; p heterogeneity by sex = 0.008) (24). Our 
results similarly suggest the association might be stronger for women, for whom we observed a 48% 
decreased risk comparing the highest and lowest 25(OH)D quintile (HR = 0.52, 95% CI 0.33-0.82), 
while we found little evidence of an association for men (HR= 0.96, 95% CI 0.61-1.52). Reasons for 
the stronger association for women are unclear and warrant further investigation (24). 
 
In our study, circulating 25(OH)D concentration appeared to be inversely associated with BRAF V600E 
positive colorectal cancer. Women are more likely than men to have a tumour with the BRAF mutation 
(30), and to have proximal (right-sided) colon tumours, which are in turn more likely than distal tumours 
to contain the BRAF mutation (31). Thus, the stronger association for women compared with men could 
potentially be explained, at least in part, by the higher frequency of BRAF+ tumours in women. We did 
not find any association between circulating 25(OH)D and KRAS+ or BRAF-/KRAS- colorectal cancer. 
Evidence regarding 25(OH)D and risk of colorectal cancers by mutation status is limited and 
inconsistent. In the Nurses’ Health Study and Health Professionals’ Follow-up Study), there was an 
inverse association between predicted 25(OH)D concentration and colorectal cancer incidence, but the 
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association did not differ by BRAF or KRAS mutation status (32). In a randomised controlled trial of 
adjuvant therapy for stage III colorectal cancer, BRAF mutations were less common in patients with 
high predicted baseline 25(OH)D and KRAS mutations were not associated with predicted 25(OH)D 
(33). Varynen et al reported a small case-control study of colorectal cancer (34). Cases with BRAF 
mutations had the lowest mean 25(OH)D, those with KRAS mutations had intermediate mean, and 
patients with neither mutation had the highest mean, although the numbers of patients were small 
(n=117) and the differences were not significant (p = 0.51). A case-control study of adenomas and 
hyperplastic polyps (part of the sessile serrated neoplasia pathway that involves BRAF mutations (35)), 
reported an inverse association between 25(OH)D and adenomas but not with hyperplastic polyps (36). 
The reasons why vitamin D might play a greater role in inducing BRAF mutations are unclear.  
 
Laboratory studies have consistently shown that the active form of vitamin D, 1,25-dihydroxyvitamin 
D (1,25(OH)2D), has potent antineoplastic effects, including inhibition of cellular proliferation, 
angiogenesis, invasion and metastasis, and induction of differentiation and apoptosis of cancer cells 
(37,38). In support of a role of vitamin D in colorectal carcinogenesis, colon epithelial cells express 25-
hydroxyvitamin D-1α-hydroxylase for local conversion of 25(OH)D to 1,25(OH)2D, which in turn can 
locally regulate cellular proliferation and differentiation in the colon (39). The 25-hydroxyvitamin D-
1α-hydroxylase enzyme is also expressed in numerous other tissues throughout the body, including the 
breast and prostate (40), and it remains unclear why vitamin D appears to be associated with some 
cancers and not with others.  
 
It has been hypothesised that vitamin D deficiency might be a marker of poor health or underlying 
undiagnosed disease, or might be the result of, rather than a cause of cancer (2). The inverse association 
we observed between 25(OH)D and colorectal cancer risk did not differ significantly by time since 
baseline blood collection, suggesting that reverse causation is unlikely to fully account for the findings. 
 
While observational studies have consistently found an inverse relationship between 25(OH)D and 
colorectal cancer incidence, to date there little evidence from randomised controlled trials to confirm 
that vitamin D plays a role in prevention of colorectal cancer (1,2,4,5). The VITAL trial found no effect 
on colorectal cancer risk, but was limited by few cases (26). Results from another large trial currently 
underway (D-Health (41)) are required to determine whether there is a causal relationship between 
vitamin D and risk of colorectal cancer, and other cancers, and to discern associations by tumour 
subtypes. 
 
Overall, it is unlikely that vitamin D has a substantial effect on breast cancer or prostate cancer risk. 
There is some evidence that 25(OH)D concentration is inversely associated with risk of colorectal 
cancer for women.  
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Table 1: Baseline characteristics of subcohort participants and those diagnosed with colorectal cancer, breast cancer, and prostate cancer during follow-upa 
 Subcohort Colorectal cancer Breast cancer Prostate cancer 
 Women Men Women Men   
n 1332 1664 284 278 659 833 
Median years of follow-up per person 14.2 14.1     
25(OH)D (nmol/L), median (IQR)b 42.9 (34.8-53.1) 54.8 (43.0-68.8) 41.0 (33.4-50.8) 53.8 (45.0-69.1) 44.0 (35.6-52.5) 57.2 (45.2-70.8) 
Age (years), median (IQR) 53.5 (46.7-61.1) 53.9 (46.0-62.0) 61.9 (54.0-66.4) 62.1 (55.1-65.8) 55.3 (47.8-62.4) 59.9 (53.8-65.2) 
Waist circumference (cm), median (IQR) 77.0 (70.6-85.7) 92.0 (86.0-98.4) 79.9 (71.3-89.0) 95.0 (89.5-100.5) 77.5 (71.0-86.0) 93.0 (87.2-99.0) 
Country of birth (%)       
Australia/New Zealand/Northern Europe 86.3 81.2 87.3 79.1 91.4 85.1 
Southern Europe 13.7 18.8 12.7 20.9 8.7 14.9 
Educational attainment (%)       
Primary school or less 10.3 12.2 12.7 18.0 7.1 12.1 
Some secondary school 44.9 31.7 44.7 33.8 45.1 30.4 
Secondary school 20.9 26.0 18.7 26.6 22.3 26.9 
Tertiary qualification 24.0 30.2 23.9 21.6 25.5 30.6 
Socioeconomic status (%)       
1st quintile (most deprived) 12.3 13.9 13.7 13.0 10.4 13.0 
2nd quintile 15.4 17.7 14.4 23.2 15.2 14.4 
3rd quintile 16.2 16.7 20.4 17.4 16.5 15.4 
4th quintile 23.6 22.5 16.9 20.3 24.7 24.3 
5th quintile (least deprived) 32.5 29.3 34.5 26.1 33.2 32.9 
Alcohol intake (%)       
Lifetime abstainer 34.5 12.8 31.0 12.2 33.1 13.5 
Former  2.8 5.8 3.2 3.2 4.0 5.2 
Current low 19.4 26.8 22.9 20.9 18.4 25.0 
Current medium 20.1 26.9 18.3 28.8 22.2 27.5 
Current high  23.3 27.7 24.7 34.9 22.3 28.9 
Smoking status (%)       
Never 67.0 43.4 62.3 37.8 68.1 45.0 
Former 24.9 42.9 25.7 52.5 23.8 46.8 
Current 8.1 13.7 12.0 9.7 8.0 8.2 
Physical activity (%)       
None 19.7 21.2 20.8 19.8 15.9 19.0 
Low 20.6 18.6 20.1 15.8 22.2 20.2 
Moderate  36.2 32.5 36.3 41.4 37.6 36.0 
High  23.6 27.6 22.9 23.0 24.3 24.9 
a numbers are prior to exclusions of people with missing data, because exclusions differ by cancer site 
b batch- and season-adjusted plasma-equivalent concentrations of 25(OH)D measured in dried blood spots 
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Table 2: Hazard ratios and 95% confidence intervals for the risk of colorectal cancer, breast cancer, and prostate cancer in relation to plasma-equivalent 
concentrations of 25-hydroxyvitamin D 
 Quintiles of 25(OH)D Per 25 nmol/L p trend 
 1 2 3 4 5   
Women        
  Range 25(OH)D (nmol/L)a 16.5-33.0 33.0-39.9 39.9-46.6 46.7-55.8 55.9-117.3   
  Median 25(OH)D (nmol/L)a 29.0 36.5 42.9 50.8 63.0   
Men        
Range 25(OH)D (nmol/L)a 15.1-40.1 40.4-50.5 50.5-59.5 59.6-72.9 72.9-181.1   
Median 25(OH)D (nmol/L)a 32.3 45.4 54.8 65.7 83.7   
Colorectal cancerb        
n cases/total 118/700 117/699 113/702 104/692 95/677 547/3470  
HR (95% CI) 1.00 (reference) 0.96 (0.71-1.29) 0.91 (0.67-1.24) 0.82 (0.60-1.13) 0.71 (0.51-0.98) 0.91 (0.78-1.07) 0.24 
Women        
n cases/total 67/262 59/263 58/264 51/262 40/261 275/1312  
HR (95% CI) 1.00 (reference) 0.82 (0.54-1.24) 0.78 (0.51-1.18) 0.73 (0.47-1.13) 0.52 (0.33-0.82) 0.75 (0.56-1.02) 0.07 
Men        
n cases/total 51/321 58/323 56/328 54/326 55/323 274/1621  
HR (95% CI) 1.00 (reference) 1.13 (0.74-1.74) 1.09 (0.70-1.69) 0.95 (0.61-1.48) 0.96 (0.61-1.52) 0.98 (0.83-1.17) 0.86 
Breast cancerb        
n cases/total 109/372 129/394 135/399 140/405 121/385 634/1955  
HR (95% CI) 1.00 (reference) 1.12 (0.81-1.56) 1.14 (0.83-1.57) 1.20 (0.87-1.65) 0.98 (0.70-1.36) 0.95 (0.79-1.15) 0.61 
Prostate cancerb        
n cases/total 142/473 147/475 160/489 189/521 186/514 824/2472  
HR (95% CI) 1.00 (reference) 0.94 (0.70-1.27) 1.10 (0.82-1.47) 1.17 (0.87-1.56) 1.11 (0.82-1.48) 1.07 (0.96-1.19) 0.21 
a Batch- and season-adjusted plasma-equivalent 25(OH)D. 
b All results are from Cox regression models with age as the timescale and stratified by sex and country of birth and further adjusted for potential confounding factors: 
educational attainment, socioeconomic status, physical activity, smoking status, alcohol consumption, and waist circumference. Colorectal cancer analyses further adjusted 
for margarine intake, and intake of processed meat. Breast cancer analyses further adjusted for parity, use of oral contraceptives, hormone replacement therapy, age at 
baseline and an interaction between age at baseline and waist circumference. 
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Figure 1: Flow diagram of Melbourne Collaborative Cohort Study participants included in the 
vitamin D and cancer case-cohort study.  
The flow diagram shows the number of participants included in analyses of breast cancer, colorectal 
cancer, and prostate cancer, and the number of cases included in analyses by tumour subtype. 
Subcohort numbers include subcohort cases. 
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Figure 2: Hazard ratios and 95% confidence intervals for risk of incident colorectal cancer, breast cancer, and prostate cancer per 25 nmol/L 
increment in plasma-equivalent 25-hydroxyvitamin D concentration according to time since baseline. 
Estimates are for batch- and season-adjusted plasma-equivalent 25(OH)D, from Cox regression models stratified by sex and country of birth and adjusted for 
educational attainment, socioeconomic status, physical activity, smoking status, alcohol consumption, and waist circumference. Colorectal cancer analyses 
further adjusted for margarine intake, and intake of processed meat. Breast cancer analyses further adjusted for parity, use of oral contraceptives, hormone 
replacement therapy, age at baseline and an interaction between age at baseline and waist circumference. The area of each square is inversely proportional to 
the variance of the log HR, and corresponding 95% confidence intervals (CIs) are plotted as lines. 
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Figure 3: Hazard ratios and 95% confidence intervals for subtypes of colorectal cancer, breast 
cancer, and prostate cancer per 25 nmol/L increment in circulating plasma-equivalent 25-
hydroxyvitamin D concentration. 
Estimates are for batch- and season-adjusted plasma-equivalent 25(OH)D, from Cox regression 
models stratified by sex and country of birth and adjusted for educational attainment, socioeconomic 
status, physical activity, smoking status, alcohol consumption, and waist circumference. Colorectal 
cancer analyses further adjusted for margarine intake, and intake of processed meat. Breast cancer 
analyses further adjusted for parity, use of oral contraceptives, hormone replacement therapy, age at 
baseline and an interaction between age at baseline and waist circumference. The area of each square 
is inversely proportional to the variance of the log HR, and corresponding 95% confidence intervals 
(CIs) are plotted as lines. 
 
 
